Drug Target Review

APRIL 7, 2025

Involved in various physiological processes, such as vision, taste, smell, immune response and neurotransmission, GPCRs are activated by various molecules including hormones, neurotransmitters and environmental stimuli, which trigger a cascade of cellular events that help regulate bodily functions.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

The Pharma Data

DECEMBER 14, 2020

The company announced positive phase 1 trial results in November that demonstrated its candidate elicited immune responses and was well-tolerated. No adverse events were observed and the reactions were similar to those seen in recovered COVID-19 patients, CureVac said ( DID , Nov. James Miessler. Source link.

Vaccine 52

Vaccine Trials Immune Response RNA 52

Drug Target Review

SEPTEMBER 8, 2023

However, recent insights indicate that it also operates beyond the nucleus, orchestrating initial events at the cell surface that trigger the activation of T cells. There are hundreds to thousands of dynamic phosphorylation events that occur during the first hour or so of T cell stimulation,” says Myers.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

JANUARY 31, 2021

Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS).

Immune Response 52

Immune Response Research Therapies Disease 52

The Pharma Data

DECEMBER 3, 2020

No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Broad Institute

FEBRUARY 11, 2025

By exploring the landscape of B cell states in tumors, and the mechanisms by which B cells control tumor growth, they hope to learn how to harness anti-tumor immune responses for treatment more effectively.

Medical Schools 52

Medical Schools Immune Response Hospitals Doctors 52

The Pharma Data

SEPTEMBER 3, 2020

The data, published today in Nature Medicine , demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Immune response was measured using immunoglobulin G (IgG) assays. Approximately 92 percent of participants in the analysis received an mRNA vaccine.

Vaccine 52

Vaccine Therapies Immune Response Disease 52

The Pharma Data

JANUARY 5, 2021

.” The clinical trial involved 24 COVID patients at one of two Miami-area hospitals who had developed severe acute respiratory distress syndrome, a condition in which the body’s immune response to a serious infection causes the lungs to fill with fluid.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

The Pharma Data

SEPTEMBER 30, 2021

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

NOVEMBER 9, 2020

Data from the event-driven trial could support global authorization and approval, including in the U.S. Depending on the overall COVID-19 attack rate, interim data in the UK trial, which is also event-driven, are expected as soon as early first quarter 2021. and globally.”. About NVX-CoV2373.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. Synlogic’s President and Chief Executive Officer.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

LifeSciVC

JULY 1, 2024

Build your social immunity. The adaptive immune response identifies and responds to highly specific antigens associated with infections and cancer. This response often involves the development of immunity thru the generation and maturation of antibodies which help eliminate threats.

Science 86

Science Immune Response Molecular Biology RNA 86

The Pharma Data

JUNE 26, 2021

In line with our global leadership and our 7 0-year history of pro tecting people with influenza v accine s , w e will always focus on developing product s that demonstrate protection beyond flu , as we believe it is critical to demonstrate protecting patients from hospitalizations due to cardiovascular events and pneumonia.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JUNE 24, 2021

Secondary objectives are to describe immune responses produced by each of the vaccines. Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer BioNTech COVID-19 Vaccine. The Pfizer?BioNTech

Vaccine 52

Vaccine Immune Response FDA Licensing 52

Alta Sciences

JANUARY 11, 2024

The in vivo nonclinical study of cell and gene therapies includes a thorough understanding of on-and-off-target activity, immune responses, and other adverse events just to name a few. However, there are significant challenges associated with the successful development of these complex, leading-edge therapies.

Therapies 52

Therapies Immune Response Disease Virus 52

Alta Sciences

JUNE 11, 2024

Attendees were encouraged to engage in several talks and presentations throughout the day, and the event organizers had done a fantastic job assembling an outstanding lineup of speakers/key industry leaders to spark extensive discussions. Of all the high-quality presentations I attended, two in particular caught my attention.

Therapies 52

Therapies Molecular Biology Immune Response Science 52

Drug Target Review

OCTOBER 17, 2024

While its involvement in the do-not-eat-me signal from cancer has inspired therapeutic development of this pathway for oncology, the function of the innate immune checkpoint we identified in 2009 1 extends to both innate and adaptive immune responses. CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses.

Immune Response 52

Immune Response Clinical Trials Trials Therapies 52

The Pharma Data

DECEMBER 23, 2020

Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported; only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. . Through week 8, no serious adverse events were reported.

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

APRIL 8, 2021

Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1. No dose-limiting toxicities were observed for THOR-707 at reported doses, up to 24 ?g/kg g/kg in combination.

Immune Response 52

Immune Response Engineering Treatment Trials 52

The Pharma Data

DECEMBER 11, 2020

. “There will be no distinction made, in part because we think there’s no adverse event that will occur, and also the protection from the vaccine actually may be more long-lived, of longer duration than that you get from the natural infection.”

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

OCTOBER 6, 2021

Fluzone High-Dose is the only influenza vaccine that has demonstrated reductions in influenza-related complications such as hospitalizations due to cardiovascular events and pneumonia, over 10 consecutive seasons in more than 34 million people aged 65 and older 1 , 2 , 3. Full results of the study will be published later this year.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

DECEMBER 28, 2020

Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition. For more information about the Company, please visit [link]. . .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. No serious adverse events related to the vaccine candidates studied were reported. CHENGDU, China , Feb.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

NOVEMBER 9, 2020

Combining ICIs with radiation therapy is emerging as a valuable strategy to “prime” an immune response and thereby increase the response rate, however the efficacy of radiation therapy is limited by toxicities related to the exposure of healthy tissues. Pneumonitis is a known adverse event associated with nivolumab.

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

NOVEMBER 18, 2020

The only notable adverse events were fatigue and headache in a small percentage of participants, 3.8 While the vaccine generated immune responses in participants, it led to lower levels of antibodies than were seen in patients that recovered from COVID-19, the researchers said in The Lancet. James Miessler. Source link.

Vaccine 52

Vaccine Government Immune Response FDA 52

The Pharma Data

JULY 23, 2021

Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS online at [link].

Vaccine 52

Vaccine Government Immune Response FDA 52

The Pharma Data

NOVEMBER 30, 2020

Interim data in this event-driven trial are expected as soon as early first quarter 2021, although the timing depends on the overall COVID-19 rate in the region. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.?Novavax?is

Clinical Development 52

Clinical Development Vaccine Clinical Trials Immune Response 52

The Pharma Data

AUGUST 20, 2020

T cell immune responses elicited by BNT162b2 are being evaluated in the German study and the companies expect to submit the data for peer review and potential publication. trial and we look forward to sharing T cell immune response data from the German trial in the near future.”. “It View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

JANUARY 22, 2021

Novavax’s vaccine is a recombinant protein vaccine adjuvanted with Novavax’s nanoparticle technology, Matrix-M, which enhances immune response in recipients. Scientists have been aiming to complete late-stage clinical studies to demonstrate the efficacy, safety and immunogenicity of NVX-CoV2373 for the prevention of Covid-19. “We

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

OCTOBER 27, 2020

Sitravatinib is an investigational spectrum-selective inhibitor of receptor tyrosine kinases (RTK) designed to enhance immune responses through the inhibition of immunosuppressive signaling. MRTX1133 is an investigational small molecule and selective KRAS G12D inhibitor in preclinical development. SOURCE Mirati Therapeutics, Inc.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

JUNE 25, 2021

Serious and severe adverse events were low in number and balanced between vaccine and placebo groups. No single adverse event term was reported by more than 1% of participants. Results: Reasserting a favorable safety profile. Preliminary safety data from PREVENT-19 showed the vaccine to be generally well-tolerated. About Novavax.

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

OCTOBER 21, 2020

We believe that ADI-001 offers the opportunity for on demand treatment, selective tumor targeting, innate and adaptive anti-tumor immune response, and durable activity in patients. “We are particularly excited to advance on our goal to exploit the therapeutic potential of our first in class engineered CAR ?? Forward-Looking Statements.

FDA 40

FDA Immune Response Engineering Clinical Trials 40

The Pharma Data

SEPTEMBER 9, 2020

producing CD8+ T cell responses, which is thought to promote an anti-viral effect. In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, CD4+ and CD8+ T-cells from splenocytes isolated from BNT162b2-immunized mice were strongly positive for IFN? The study is an event-driven trial. Argentina and Brazil.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

NOVEMBER 10, 2020

Oral administration of anti-CD3 monoclonal antibody is a novel approach to induce an anti-inflammatory immune response to suppress inflammation by inducing T regulatory (Tregs) cells in animal studies 3 ,4. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Clinical Trials 40

Clinical Trials Science Disease Trials 40